In a nutshell This study examined the use of bisphosphonate treatment for bone protection in patients with multiple myeloma. This study concluded that many patients do not receive adequate bone protection. Some background In multiple myeloma, bones are commonly affected, leading to bone destruction. Bisphosphonates are a group of drugs that prevent...
Read More
In a nutshell This paper reviewed the effect of thearpies that act on the immune system on the risk of infection. The study concluded that patients receiving these drugs are at a high risk of serious infection. Some background Treatment for multiple myeloma now generally includes immunomodulators and stem cell transplantation....
Read MoreIn a nutshell This study examined the effect of lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma. This study concluded that the treatment combination was effective and results were similar to that seen in clinical trials. Some background Lenalidomide is a type of immunotherapy (stimulates the immune system to fight...
Read More
In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...
Read MoreIn a nutshell This paper studied the effectiveness of daratumumab (Darzalex) in multiple myeloma patients who had received at least 1 previous treatment. This study concluded that daratumumab was more effective when used in combination with lenalidomide or bortezomib. Some background There is no standard treatment option for multiple myeloma that...
Read MoreIn a nutshell This paper reviewed the adverse (negative) events associated with new treatments in multiple myeloma. Patients should be closely monitored for adverse events. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Treatment includes the use of various types of medications. Adverse events...
Read More
In a nutshell This paper reviewed the effect of elozutumab (Empliciti) in the treatment of relapsed or refractory multiple myeloma. This study concluded that elozutumab with lenalidomide (Revlimid) and dexamethasone (Ozurdex) can be considered in relapsed or refractory multiple myeloma. Some background Multiple myeloma...
Read More
In a nutshell This paper studied the risk of adverse events in patients who receive treatment for multiple myeloma. The use of new drugs increased the risk of low blood count, peripheral neuropathy and blood clots. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Multiple myeloma can be treated with drugs...
Read More
In a nutshell This paper reviewed the risk of heart disease in patients receiving treatment for multiple myeloma. Reducing the risk of heart disease is important in patients with multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells of blood. Treatment for multiple myeloma involves a group of drugs called proteasome...
Read More
The adrenal glands-which are also called suprarenal glands-are part of the endocrine system and are found on the top of each kidney. How the endocrine system hormones work Hormones secreted from glands of the endocrine system travel in the bloodstream to target cells. Target cells have receptors that are specific to each hormone. The hormones and receptors...
Read More
Thirty-eight states in the US have passed “Right To Try” laws. These are laws that are created to give terminally ill patients who have run out of options access to experimental drugs that have not completed the FDA approval process. There is an effort underway to pass this type of legislation on a federal level. On February 8, the #LCSM (Lung...
Read More
In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...
Read More
